ENLV · Enlivex Ltd. · Metrics
$1.27
+0.00 (+0.00%)
At close · Nov 6
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Market Cap
$1.95M
Shares
1.53M
Volume · Nov 6
18.16K
Avg daily vol (9 sessions)
62.3K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
ENLV metrics
38 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$1.27
Market cap
$1.95M
Price action
23 metricsPrice change (1W)
-50.0%
Price change (30D)
-53.0%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
1.53M
Valuation
12 metricsP / E (TTM)
0.0
Trailing earnings · reciprocal yield 163,951.6%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.0
reciprocal yield 200,358.5%
FCF yield
-800.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
163,951.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-03-25
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$24.25M
Net income (TTM)
$3.19B
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,115.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
81.8%
Return on assets
65.1%
Debt / equity
—
Current ratio
119.4
EBITDA (TTM)
—
Free cash flow (TTM)
−$15.57M
Quick ratio
119.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$5.52M
Total assets
$4.90B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$15.53M
Capital expenditures (TTM)
$38,000
R&D (TTM)
$11.14M
SG&A (TTM)
—
Stock compensation (TTM)
$7.93M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
27
13F filer change QoQ
-8
Institutional ownership
1.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+19.7%
Holder tenure
3.6
Price vs estimated holder cost
-37.9%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
0.6%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
51 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—